-

Kevin Koch has served as the President and Chief Executive Officer of Edgewise Therapeutics since July 2017 and a Venture Partner at OrbiMed Advisors, LLC since May 2016. Dr. Koch has been active in the life science industry for over 25 years with a focus on drug discovery, translational medicine and clinical development. Prior to joining OrbiMed, Dr. Koch acted as a consultant in the biotech industry from September 2015 to May 2016. Prior to acting as a consultant, Dr. Koch served as the Senior Vice President of Drug Discovery, Chemical and Molecular Therapeutics at Biogen, Inc. from December 2013 to September 2015, where he managed global drug discovery and biomarker development as well as the immunology and hematology teams.  Dr. Koch was a co-founder of Array Biopharma Inc. and served as its President, Chief Scientific Officer and Director from May 1998 to November 2013. While there, he built a fully integrated R&D team that oversaw the invention of over 20 clinical development candidates in the multiple therapeutic areas. Prior to Array, Dr. Koch served as an Associate Director of Medicinal Chemistry and Project Leader for the Protease Inhibitor and New Leads project teams from May 1995 to April 1998 for Amgen Inc. From September 1988 to May 1995, Dr. Koch held various positions with Pfizer Central Research, including Senior Research Investigator, Senior Research Scientist, and Project Coordinator for the Cellular Migration and Immunology Project Teams. 

Dr. Koch is the Treasurer and Board Member of the Inflammation Research Association. Dr. Koch has been a Director of miRagen Therapeutics, Inc. since February 2017.  He is a Founding Board Member of Skyhawk Therapeutics, Inc. Dr. Koch serves on the boards of Neurogastrx, Inc. and Encycle Therapeutics and consults with several life science companies. He is a Director of Skyhawk Therapeutics, Inc. He is a co-author or inventor of multiple patents and publications. Dr. Koch received a B.S. in Chemistry and Biochemistry from State University of New York, Stony Brook, an M.S. in Organic Chemistry from University of Rochester and a Ph.D. in Synthetic Organic Chemistry from University of Rochester.